Dihydroartemisinin could enhance the anticancer activity by increasing ferroptosis in GBM through inhibiting the PERK-ATF4-HSPA5-GPX4 pathway (Chen et al. 2019a, b). Here, HSPA5 is linked to glioblastoma.